Summit Therapeutics SMMT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -271%-64.8pp | -206.1%+86.4pp | -292.5%+35.8pp | -328.3%-204pp | -123.9%-29.0pp | |
| Liquidity | ||||||
| Current ratio | 7.4×-2.5× | 9.9×+6.1× | 3.8×-1.3× | 5.1×-5.5× | 10.6×+0.5× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.70-20.1% | $0.88+241% | $0.26-26.0% | $0.35-25.1% | $0.47-13.8% | |
| Valuation | ||||||
| Market capitalization | $14.7B+12.9% | $13.02B-15.2% | $15.35B-1.2% | $15.54B+9.2% | $14.23B+8.1% | |
| Price / book | 26.9×+7.2× | 19.8×-60.1× | 79.8×+19.9× | 59.9×+18.6× | 41.3×+7.5× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Summit Therapeutics's ratios come from?
- Every ratio is computed from Summit Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.